{
    "clinical_study": {
        "@rank": "72290", 
        "acronym": "VRI01", 
        "arm_group": [
            {
                "arm_group_label": "MVA HIV-B and LIPO-5 vaccines", 
                "arm_group_type": "Experimental", 
                "description": "MVA HIV-B primes 0,5 milliliter (mL) Intramuscular at Week 0 and Week 8 LIPO-5 1mL Intramuscular boosts at Week 20 and Week 28"
            }, 
            {
                "arm_group_label": "LIPO-5 and MVA HIV-B vaccines", 
                "arm_group_type": "Experimental", 
                "description": "LIPO-5 primes 1mL intramuscular at Week 0 and Week 8 and MVA HIV-B 0,5mL intramuscular boosts at Week 20 and Week 28"
            }, 
            {
                "arm_group_label": "GTU-MultiHIV B and LIPO-5 vaccines", 
                "arm_group_type": "Experimental", 
                "description": "GTU-MultiHIV B 0,5mL intramuscular via Biojector 2000 and 0,5mL intradermic primes at Week 0, Week 4 and Week 12 and LIPO-5 1mL intramuscular boosts at Week 20 and Week 28"
            }, 
            {
                "arm_group_label": "GTU-MultiHIV B and MVA HIV-B vaccines", 
                "arm_group_type": "Experimental", 
                "description": "GTU-MultiHIV B 0,5mL intramuscular via Biojector 2000 and 0,5mL intradermic primes at Week 0, Week 4 and Week 12 and MVA HIV-B 0,5mL intramuscular boosts at Week 20 and Week 28"
            }
        ], 
        "brief_summary": {
            "textblock": "The development of a safe and effective HIV-1 vaccine strategy would probably be the best\n      solution for the ultimate control of the worldwide AIDS pandemic. Heterologous prime-boost\n      immunisations are today considered promising HIV prophylactic vaccine strategies. It is thus\n      relevant to pursue the development of different candidate vaccines in prime-boost vaccine\n      strategies to identify the most promising prime-boost combinations and to integrate\n      scientific inquiry into trial protocols from the beginning to maximize learning\n      opportunities."
        }, 
        "brief_title": "Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV Infection", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Phase I/II, multicenter, national, open-label, randomized trial HIV including 4 prophylactic\n      prime-boost HIV vaccines strategies:\n\n      Volunteers are randomly allocated in a 1:1:1:1 ratio at trial entry to 4 parallel arms with\n      the following prime-boost strategies:\n\n      Arm 1. MVA HIV-B primes at Week 0 and Week 8 + LIPO-5 boosts at Week 20 and Week 28 Arm 2.\n      LIPO-5 primes  at Week 0 and Week 8 + MVA HIV-B boosts at Week 20 and Week 28 Arm 3.\n      GTU-MultiHIV B primes at Week 0, Week 4 and Week 12 + LIPO-5 boosts at Week 20 and Week 28\n      Arm 4. GTU-MultiHIV B primes at Week 0, Week 4 and Week 12 + MVA HIV-B boosts at Week 20 and\n      Week 28"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written and signed informed consent\n\n          -  Subject at low risk to contract HIV i.e.\n\n               -  no history of injecting drug use in the previous ten years;\n\n               -  no gonorrhea or syphilis in the last six months;\n\n               -  no high risk partner (e.g. injecting drug user, HIV positive partner) either\n                  currently or within the past six months ;\n\n               -  no unprotected anal intercourse in the last six months, outside a relationship\n                  with a regular partner known/presumed to be HIV negative ;\n\n               -  no unprotected vaginal intercourse in the last six months outside a relationship\n                  with a regular known/presumed HIV negative partner\n\n          -  Available for follow-up for the duration of the study (56 weeks from screening)\n\n          -  Willing to undergo a HIV test\n\n          -  Willing to undergo a genital infection screen\n\n          -  If heterosexually active female, using an effective method of contraception with\n             partner (combined oral contraceptive pill; injectable contraceptive; contraceptive\n             implant/patch; IntraUterine Contraceptive Device (IUCD); consistent record with\n             condoms if using these; physiological or anatomical sterility in self or partner)\n             from 14 days prior to the first vaccination until 4 months after the last, and\n             willing to undergo urine pregnancy tests prior to each vaccination\n\n          -  If heterosexually active male, using an effective method of contraception with their\n             partner from the first day of vaccination until 4 months after the last vaccination\n\n          -  Subject registered in French Health ministry computerised file and authorised to\n             participate in a clinical trial\n\n          -  Subject covered by Health Insurance\n\n        Exclusion Criteria:\n\n          -  Clinically relevant abnormality on history or examination including history of:\n\n          -  uncontrolled infection;\n\n          -  autoimmune disease;\n\n          -  immunodeficiency or use of immunosuppressive drugs within 3 months prior to\n             screening;\n\n          -  cancer;\n\n          -  chronic diseases requiring long-term treatment whose interruption during the trial\n             has no impact on the health status in the short or long-term\n\n          -  Receipt of live attenuated vaccine within 60 days or other vaccine within 14 days\n             prior to W0\n\n          -  Planned receipt of other vaccines than those planned by the protocol and those\n             recommended in France (excluding live attenuated vaccines) during the trial follow-up\n             (reference : Weekly Epidemiological Newsletter 14-15 dated on April 10th, 2012\n             (Bulletin Epid\u00e9miologique hebdomadaire 14-15 / 10 avril 2012))\n\n          -  Receipt of blood products or immunoglobin within 4 months prior to screening\n\n          -  History of severe local or general reaction to vaccination defined as\n\n          -  local: extensive, indurated redness and swelling involving most of the antero-lateral\n             thigh or the major circumference of the arm, not resolving within 72 hours\n\n          -  general: fever \u2265 39.5\u00b0C within 48 hours; anaphylaxis; bronchospasm; laryngeal oedema;\n             collapse; convulsions or encephalopathy within 72 hours\n\n          -  Positive for ANA antibodies at a titer considered clinically relevant by the\n             physician (local cut-off or \u2264 1/320, whatever is lower).\n\n          -  HIV-1 or HIV-2 positive or indeterminate at screening\n\n          -  Woman expecting to conceive during the study period\n\n          -  Pregnant or breastfeeding woman\n\n          -  Grade 1 or above routine laboratory parameters\n\n          -  Known hypersensitivity to aminoglycosides and eggs (as used in the vaccine production\n             processes)\n\n          -  Known hypersensitivity to one of the trial vaccine components, the metabolites or\n             formulation excipients\n\n          -  Known history of smallpox vaccination\n\n          -  Anticipated non-compliance with the protocol\n\n          -  Participation in another clinical trial with an on-going exclusion period at\n             screening\n\n          -  Participation in a HIV preventive vaccine clinical trial (unless participant were\n             randomized in placebo arm)\n\n          -  Subject under legal guardianship or incapacitation\n\n          -  Subject who is an active blood donor and unwilling to interrupt blood donations\n             during the his/her participation in the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "92", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02038842", 
            "org_study_id": "2012-002456-14"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "MVA HIV-B and LIPO-5 vaccines", 
                    "LIPO-5 and MVA HIV-B vaccines", 
                    "GTU-MultiHIV B and LIPO-5 vaccines"
                ], 
                "description": "LIPO-5: 1mL IntraMuscular, 2 shots;", 
                "intervention_name": "LIPO-5", 
                "intervention_type": "Biological", 
                "other_name": [
                    "ANRS LIPO-5 vaccine candidate", 
                    "ANRS MVA HIV-B (MVATG17401) vaccine candidate", 
                    "FIT Biotech GTU-MultiHIV B vaccine candidate"
                ]
            }, 
            {
                "arm_group_label": [
                    "MVA HIV-B and LIPO-5 vaccines", 
                    "LIPO-5 and MVA HIV-B vaccines", 
                    "GTU-MultiHIV B and MVA HIV-B vaccines"
                ], 
                "description": "MVA HIV-B (MVATG17401): 0.5mL IntraMuscular, 2 shots;", 
                "intervention_name": "MVA HIV-B (MVATG17401)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "GTU-MultiHIV B and LIPO-5 vaccines", 
                    "GTU-MultiHIV B and MVA HIV-B vaccines"
                ], 
                "description": "GTU\u00ae-MultiHIV B: 0.5 mL IM via Biojector\u00ae 2000 and 0.5mL IntraDermic, 3 shots", 
                "intervention_name": "GTU\u00ae-MultiHIV B: 0.5 mL IM via Biojector\u00ae 2000 and 0.5mL IntraDermic, 3 shots", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 16, 2014", 
        "location": {
            "contact": {
                "email": "jean-daniel.lelievre@hmn.aphp.fr", 
                "last_name": "Jean Daniel LELIEVRE, Pr", 
                "phone": "+33149814442"
            }, 
            "facility": {
                "address": {
                    "city": "Creteil", 
                    "country": "France", 
                    "zip": "94010"
                }, 
                "name": "Service d'Immunologie Clinique 51, avenue du Marechal de Lattre de Tassigny"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "4", 
        "official_title": "Phase I/II Open-label Randomized Multicenter Trial to Assess Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates (MVA HIV-B/ LIPO-5; LIPO-5/MVA HIV-B; GTU\u00ae-MultiHIV B / LIPO-5; GTU\u00ae-MultiHIV B/MVA HIV-B) in Healthy Volunteers at Low Risk of HIV Infection", 
        "overall_contact": {
            "email": "jean-daniel.lelievre@hmn.aphp.fr", 
            "last_name": "Jean-Daniel LELIEVRE, Pr", 
            "phone": "+33 149812455"
        }, 
        "overall_official": [
            {
                "affiliation": "Hopital Henri Mondor", 
                "last_name": "Jean-Daniel LELIEVRE   Study Chair, Pr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Inserm Unit 897", 
                "last_name": "Laura RICHERT   Methodologist, Dr", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "\u2022 Proportion of participants without any grade 3 or 4 adverse events (clinical or biological) related to MVA-vaccine immunisation, reported from Week 0 to Week 2 in arm 1", 
                "measure": "Evaluation of the safety of MVA HIV-B at Week 2 in arm 1", 
                "safety_issue": "Yes", 
                "time_frame": "Visit Week 2"
            }, 
            {
                "description": "Proportion of participants with a HIV-specific Interferon-gamma Enzyme Linked Immunosorbent SPOT (IFN-\u03b3 ELISPOT) response in each of the 4 arms, defined by a positive response to at least one of the stimulating HIV peptide pools (15-mer pools covering Env, Gag, Pol, and Nef) measured in stimulated Peripheral Blood Mononuclear Cell (PBMC) by a standard IFN-\u03b3 ELISPOT assay at Week 30, i.e. 2 weeks after the last vaccine immunisation.", 
                "measure": "To discard vaccine strategies with an insufficient level of immunogenicity, defined by HIV-specific IFN-\u03b3-ELISPOT responses, among  4 HIV prophylactic prime-boost combinations in healthy volunteers at low risk of HIV infection", 
                "safety_issue": "No", 
                "time_frame": "Visit Week 30"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02038842"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Grade 1 or more clinical and laboratory adverse events related to vaccine immunisation: proportion of participants with an event; number, nature, grade and time of occurrence.\nAny event related to vaccine immunisation, leading to discontinuation of the immunisation regimen: proportion of participants with an event; number, nature, grade and time of occurrence.\nGrade 3 or 4 clinical and laboratory adverse events, validated by the Endpoint Review Committee, regardless of the relationship to vaccine immunisation: proportion of participants with an event; number, nature, grade and time of occurrence.\nSerious adverse events, regardless of the relationship to vaccine immunisation: proportion of participants with an event; number, nature, grade and time of occurrence.", 
                "measure": "To assess the tolerance of each prime-boost combination", 
                "safety_issue": "Yes", 
                "time_frame": "visit Week 52"
            }, 
            {
                "description": "In all participants having received at least 1 dose of vaccine:\nProportion of HIV-specific IFN-\u03b3-ELISPOT responders\nEx-vivo transcriptome analysis\nIn participants having received at least 1 dose of vaccine and a positive IFN-\u03b3-ELISPOT response at the considered timepoint:\n\u2022 Magnitude and breadth of HIV-specific IFN-\u03b3-ELISPOT responses, measured following stimulation of PBMC with HIV-1 peptide pools 2 weeks after each vaccine immunisation.\nIn a random sample of participants, having received at least 1 dose of vaccine, with random sampling stratified on trial arm and ELISPOT response at Week 30:\nProduction of cytokine (IFN- \u03b3, Interleukin-2 (IL-2), Tumor Necrosis Factor-alfa (TNF-alfa)) by HIV-specific  Cluster of Differentiation 8 (CD8+) and Cluster of Differentiation 4 (CD4+) T cells\nSecretion of cytokines by PBMC measured by Luminex\u00ae\nGene expression profile of PBMC measured by transcriptome analysis", 
                "measure": "To assess for each prime-boost combination the type of vaccine-induced T cell response", 
                "safety_issue": "No", 
                "time_frame": "Visit Week 30"
            }
        ], 
        "source": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}